The impact of the immunotherapy revolution on lymph nodal surgery
- 1 June 2020
- journal article
- editorial
- Published by Elsevier in Bulletin du Cancer
- Vol. 107 (6) , 640-641
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- The new era of adjuvant therapies for melanomaNature Reviews Clinical Oncology, 2018
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaNew England Journal of Medicine, 2018
- Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated MelanomaNew England Journal of Medicine, 2017
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017
- Completion Dissection or Observation for Sentinel-Node Metastasis in MelanomaNew England Journal of Medicine, 2017
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyNew England Journal of Medicine, 2016
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2016
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015
- Cutaneous melanomaThe Lancet, 2014
- Sentinel-Node Biopsy or Nodal Observation in MelanomaNew England Journal of Medicine, 2006